Print this page
immunotherapy
-
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery.
Protocol: 032601Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery.
Protocol: 032601Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Protocol: 042210Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
Pilot Study to Investigate the Metabolic Pathways in Hormone Receptor-Positive/HER2-Negative Breast Cancer.
Protocol: 042210Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative
(HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor.
Protocol: 042502Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination with Chemotherapy versus Placebo with Chemotherapy in Patients with Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease.
Protocol: 042601Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative
(HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor.
Protocol: 042502Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination with Chemotherapy versus Placebo with Chemotherapy in Patients with Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease.
Protocol: 042601Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants with KRAS-Altered Advanced or Metastatic Solid Tumors.
Protocol: 052506Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver